Therapies that involved inhibition of immune regulatory checkpoints, i.e., PD-1, PD-ligands (PD-L1, PD-L2), and CTLA-4 have shown remarkable success in a broad range of hematological malignancies and solid tumors, leading to a substantial enhancement in overall survival rates. The gene discussed is PDCD1; the disease is hematologic disorder.